CENTOGENE’s Lysosomal Storage Disorders Research to be Presented at the 14th Annual WORLDSymposium

Feb. 1, 2018 13:00 UTC

Four poster presentations focused on Fabry, Gaucher and Niemann-Pick Disease


ROSTOCK, Germany--(BUSINESS WIRE)-- Centogene, the worldwide leader in diagnosing, profiling, tracking and elucidating rare diseases for patients, clinicians and pharmaceutical partners, today announced that results from its scientific research focused on biomarkers and genetic data for rare hereditary diseases will be the core of four poster presentations at the 14th Annual WORLDSymposium™. The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.

The following posters will be presented on Tuesday, February 6, 4:30-6:30 pm PT.

  • “Lyso-SM-509 as highly sensitive biomarker for Niemann-Pick A/B and C diseases: a three years experience”
  • “Biochemical and genetic characteristics of the largest world-wide Fabry cohort reported to present”
  • “Glucosylphingosine concentration in the blood of Gaucher patients reflects the severity of GBA mutations – data from a large global cohort”
  • “Quantification of Glucosylshingosine (Lyso-Gb1) for the diagnosis and monitoring of Gaucher disease”

“Our mission at CENTOGENE is clear—to help identify patients with rare diseases at the earliest possible time and help accelerate drug discovery and development of orphan drugs worldwide,” said Professor Arndt Rolfs, M.D., CEO of CENTOGENE. “The data we will be presenting at this conference will support the development of personalized therapies of the future and further validate our capabilities.”

CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with genetic diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database, CentoMD® and solutions for pharmaceutical companies developing life-changing orphan drugs.

As one of the most diversified and largest genetic testing companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients and their families. www.centogene.com; www.centoMD.com



Media Contact:
MacDougall Biomedical Communications
Lauren Arnold, 781-235-3060
Company Contact:
Doreen Niemann, +49 381 80113 510




Back to news